Phaseline

Companies › Viridian Therapeutics

Viridian Therapeutics: clinical trials, targets and expected readouts

1 active drug program in 3 registered trials: 3 Phase 3; Ophthalmology; next expected readout Nov 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
VRDN-003
Humanized monoclonal antibody directed against insulin-like growth factor-1 receptor (IGF-
IGF1RPhase 3Thyroid Eye Disease (TED); Thyroid Eye DiseaseNov 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06812325VRDN-003Phase 3Thyroid Eye Disease (TED)OphthalmologyApr 2026
NCT06625411VRDN-003Phase 3Thyroid Eye DiseaseOphthalmologyNov 2026
NCT06625398VRDN-003Phase 3Thyroid Eye DiseaseOphthalmologyDec 2026

Specialist investors

Held by 12 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

IGF1R (1)

Companies with the same targets

Innovent Biologics (Suzhou) OHB Neonatology Amgen Candid Therapeutics Minghui Pharmaceutical (Hangzhou) Sling Therapeutics Zai Lab (Shanghai)

Companies built like this

Cloudbreak Therapeutics Omikron Italia S.r.l. Aurion Biotech Smilebiotek Zhuhai Beletalent (Zhuhai) Pharmaceutical

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.